ADMA Biologics (ADMA) Projected to Post Quarterly Earnings on Wednesday

ADMA Biologics (NASDAQ:ADMA) is expected to be posting its Q1 2025 quarterly earnings results after the market closes on Wednesday, May 7th. Analysts expect the company to announce earnings of $0.16 per share and revenue of $116.40 million for the quarter.

ADMA Biologics Stock Up 0.8 %

ADMA stock opened at $23.71 on Tuesday. The business has a 50-day moving average of $19.76 and a 200-day moving average of $18.59. ADMA Biologics has a fifty-two week low of $6.72 and a fifty-two week high of $25.67. The stock has a market capitalization of $5.63 billion, a P/E ratio of 84.68 and a beta of 0.57. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.